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Abstract
Purpose: Combined immunomodulatory and antiviral
treatment  was  administered  to  three  patients  with
newly diagnosed HIV-associated primary central ner-
vous system lymphoma (PCnsl) in an attempt to im-
prove outcomes. 
Patients and methods: Three patients from our institu-
tion who were recently diagnosed with HIV-associated
PCnsl  received  intravenous  azidothymidine  (aZT)
1.6  gr.  bid  for  two  weeks,  followed  by  oral  aZT
250mg bid from day 15. In addition, complementary
highly  active  antiretroviral  therapy  (HaaRT)  with  a
second  nucleoside  reverse  transcriptase  inhibitor
(nRTI)  plus  one  protease  inhibitor  (PI)  and  inter-
leukin  2  (Il-2)  subcutaneously  2  million  units  twice
daily (bid) plus foscarnet 90mg/kg bid were adminis-
tered on days 1-14. one patient received anti-Epstein-
Barr  virus  (EBV)-maintenance  therapy  with  ganci-
clovir, followed by cidofovir [1]. 
Results: all  patients  experienced  progressive  disease
while  on  induction  therapy,  and  switched  early  to
whole-brain radiation therapy (wBRT) as second line-
treatment. no grade 3 or 4 toxicities were observed.
Two patients died on days 50 and 166 respectively due
to  progressive  disease.  The  third  patient  with  histo  -
logically proven lymphoproliferation and only suspect-
ed PCnsl remained alive at 53 months. He was on
HaaRT  and  remained  clinically  and  neurologically
stable.
Conclusion: although Il-2, HaaRT, high-dose aZT
and foscarnet are used for other HIV-related condi-
tions, they did not demonstrate benefit in lymphoma
remission for 2 HIV- associated PCnsl patients. The
third patient went into delayed remission after addi-
tional radiotherapy and was in good clinical and neu-
rological health status over 53 months after diagnosis.
InTRoduCTIon
HIV-associated PCnsl remains difficult to treat. HIV
infection induces a deficient immunologic milieu that
enables other oncogenic viruses such as EBV to es-
cape  immune  control  in  a  multifactorial  way,  which
can lead to the onset of lymphoma [2]. The incidence
of HIV-related PCnsl has decreased since the wide-
spread  introduction  of  HaaRT  [3].  Presentation  of
the disease is more frequent in persons with reduced
performance  status,  Cd4-counts  below  100/µl  and
high HIV viremia levels [4, 5, 6].
In  immunocompetent  populations,  outcome  and
toxicity of different therapy regimens are largely age-
dependent. significantly reduced survival and neuro-
toxicity  rates  of  up  to  90%  occur  with  combined
chemotherapy-radiation regimens in the above 60 year
age  group.  In  all  age  groups,  combination  radio-
chemotherapies, with mostly intrathecal (it) adminis-
tration  of  methotrexate  (MTX)  and/or  cytarabine,
prolong  overall  median  survival  rates  by  up  to  55
months [7-9]. However, they can cause increased treat-
ment-associated mortality, with high rates of infection
and  neurotoxicity.  Intensive  chemotherapy-only  regi-
mens  show  less  neurotoxicity  with  similar  survival
rates [7-10]. Higher response rates are obtained with
intensive  autologous  stem-cell-rescue  protocols  [11-
14].
In contrast to therapeutic success demonstrated for
immunocompetent patients, the outcome of HIV-as-
sociated PCnsl is still considered poor [6,15]. Median
survival rates range from four to six weeks with best
supportive care alone and 3 to 5 months with cranial
radiation treatment [4, 15-17]. Most HIV-positive PC-
nsl patients are in clinically poor condition, and have
advanced immunosuppression. Moreover, HIV-associ-
ated leukoencephalopathy in advanced HIV disease is
frequent, considering that neurotoxicity is one of the
most  frequent  debilitating  side  effects  in  combined
chemo-radiotherapy protocols.
HaaRT  induced  immune  recovery  improves  sur-
vival  of  patients  with  aIds-associated  PCnsl  and
systemic lymphoma, but these patients still have re-
duced overall survival along with higher treatment-re-
lated  mortality  than  HIV-negative  patients  [4,  6,  15,
18, 19]. The highest survival rates were reported in a
german survey with HaaRT and radiotherapy 40gy
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18  months.  steroids  had  no  prognostic  benefit  and
most PCnsl-patients (n = 23/29) were not eligible
for any treatment [4]. HaaRT has been used alone for
HIV-related PCnsl in patients with poor clinical sta-
tus, patients who have declined other therapies, and in
those experiencing failing therapies. The impact of cu-
rative HaaRT of HIV related PCnsl has been re-
ported in five single cases [20-23].
antiviral and immune-based therapy of HIV-related
PCnsl was suggested by Raez et al. [1]: 5 aRT-naive
HIV-positive  patients  diagnosed  with  PCnsl  were
treated  with  ganciclovir,  aZT  and  interleukin-2  for
two weeks and ganciclovir maintenance therapy. long
lasting  remission  and  a  marked  response  after  two
weeks of treatment was reported in four out of five
patients: two patients were alive and disease-free 22
and 13 months later, one died at month seven due to
sepsis,  one  died  after  four  months  with  progressive
disease, and one patient was lost to follow-up in partial
remission after changing to radiation-therapy due to
CTC  grade  4-neutropenia  and  thrombocytopenia  at
week four. aboulafia, et al. [5] adopted a similar treat-
ment strategy with one out of four patients remaining
in complete remission after more than four years of
follow-up.
we report three patients who were treated at our in-
stitution following a modified treatment plan originally
published by Raez. 
METHods - 3 CasE REPoRTs
Doses and regimens: Intravenous aZT 1.6 gr. bid on
days 1-14, then oral aZT 250mg bid from day 15; on-
going HaaRT with one additional nRTI as HaaRT-
backbones, plus one protease inhibitor (lopinavir/ri-
tonavir  or  nelfinavir  according  to  individual  condi-
tions),  orally  bid  in  standard  doses;  Il-2  subcuta-
neously two million units bid at days 1-14; foscarnet
bid 90mg per kilogram body weight on days 1-14 in
conjunction with one litre of saline bid to prevent re-
nal failure. Maintenance therapy with foscarnet (alter-
natively  ganciclovir  or  cidofovir  in  one  patient)  was
administered  according  to  patient  clinical  status  and
individual toxicities. 
In case of clinical or radiological disease progres-
sion,  standard  therapy  with  radiation  and  ongoing
HaaRT was started immediately. Cerebral computer-
ized transaxial tomography (CTT) scan controls were
performed on days 7 and 14 after the start of treat-
ment,  unless  there  was  clinical  deterioration,  when
CCT scans were performed earlier.
The protocol was presented to the german work-
ing group for HIV-associated lymphomas. all patients
underwent  a  brain  biopsy  that  showed  large  B-cell
lymphomas  of  high  malignancy  in  two  patients  and
lymphoproliferative  disease  with  a  large  amount  of
necrotic tissue that was highly suspicious for nHl in
the third patient despite lack of proven monoclonality.
staging results for systemic lymphoma resulted nega-
tive. 
a  treatment  plan  was  adapted  and  proposed  ac-
cording to each patient’s clinical status, and informed
consent was obtained.
REsulTs
PaTIEnT 1
Patient 1 was a 33-year-old MsM male, who had been
diagnosed  HIV-positive  since  1995.  His  Cd4-count
was 16/µl and at the time lymphoma diagnosis, he was
aRT-naive. He also had clinical signs of kaposi-sarco-
ma with lesions on skin, tongue, palate and glans penis
that had been treated for four months with systemic li-
posomal doxorubicin. 
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foscarnet.
Pat. 1 at treatment start.
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carinii pneumonia, which had been treated successfully
four weeks prior to the lymphoma diagnosis. This was
followed by three weeks of ongoing treatment for his-
tologically  proven  pulmonary  tuberculosis  and  oral
candidiasis. subsequently, a 5 cm lesion in the basal
ganglia with extensive perifocal oedema was demon-
strated by CCT scan, which had been performed be-
cause  of  a  history  of  headaches  and  grand  mal
seizures.  a  presumptive  diagnosis  of  cerebral  toxo-
plasmosis was made, and empiric anti-toxoplasmosis
therapy was initiated. after one week of treatment, the
tumour diameter increased. a stereotactic brain biopsy
was performed and revealed a highly malignant, large
B-cell lymphoma (lCa pos., Cd20 pos., Prol.-MIB-1
50%, Cd30 neg., EBV-markers not performed). 
The patient was treated for 13 days according to the
aforementioned  treatment  plan  concomitant  to  his
anti-tuberculosis therapy (isoniazid, rifampicin, etham-
butol, pyrazinamide), which was well tolerated. High
dose  aZT,  lamivudine  and  saquinavir  boostered  by 
ritonavir were selected for the HaaRT regimen. due
to  increased  intracranial  pressure,  dexamethasone
24mg/day  was  added.  Tumour  regression  could  not
demonstrated by CCT scan on days 7 and 13, so whole
brain  radiotherapy  (wBRT)  was  initiated.  follow-up
immune status was not performed. after a cumulative
dose of 20 gray, wBRT was interrupted because of
clinical  deterioration.  The  dexamethasone  dose  was
raised to 80 mg/day. The patient expired due to lym-
phoma  progression  after  discharge  to  his  home,  50
days after diagnosis and 80 days after onset of signs
and symptoms. 
PaTIEnT 2
Patient 2 was a 23-year-old IVdu male (men sex fe-
male), who had been diagnosed HIV-positive for two
years (Cd4-count 50/µl, 13%, Ratio 0.2, aRT-na￯ve,
HIV-viral  load  522.600  c/ml).  He  had  a  history  of
wasting syndrome, chronic hepatitis C and paranoid
psychosis. He was hospitalized for a 2 month exacer-
bation  of  the  chronic  paranoid  psychosis  and  fever 
of unknown origin. a diagnosis of systemic crypto-
coccosis,  manifested  with  fever,  elevated  serum-titre
of 1 : 40/1 : 320 and repeated negative Csf-findings,
was confirmed 2 months before the PCnsl diagnosis.
He  was  treated  with  fluconazole,  which  resulted  in
clinical resolution of the cryptococcosis. He had also
been diagnosed with pneumonia due to s.pneumoniae,
6 weeks before the PCnsl diagnosis, and was suc-
cessfully  treated  with  IV  ampicillin/sulbactam.  Two
weeks later, due to a 2 cm contrast enhancing cerebral
focus, empiric toxoplasmosis therapy was initiated for
2 weeks. The patient developed left sided paralysis and
CCT scan revealed that the cerebral focus had devel-
oped into a rapidly growing 4 cm parietal mass with
accompanying oedema, and normal cytological, HsV-
consensus-PCR  and  microbiological  Csf  findings.
Brain biopsy demonstrated an EBV-associated diffuse
large B-cell-lymphoma (Cd20+, MIB-1 60%, lMP+).
The initial tumour growth appeared to stop after one
week with the aforementioned treatment plan, which
included  HaaRT  with  lamivudine  and  nelfinavir.
However, over the total course of three weeks tumour
size progressed to 5 cm with a slight midline shift. His
Cd4-count  increased  two  weeks  after  initiation  of
HaaRT and Il-2 to 810/µl (52%, Cd4/Cd8 ratio
1.5), and HIV-viral load decreased to 1840 copies/ml.
Radiation therapy (40gy) was initiated followed with
concomitant dexamethasone. slight partial tumour re-
gression was observed on day 11 after start of radia-
tion therapy. However, the patient had minimal signs
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Pat. 2 at treatment start. 
Pat. 2 after 2 weeks of treatment with Il-2, aZT, HaaRT,
foscarnet.
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psychosis. despite support by nurses in hospice care,
medication adherence was inadequate due to the se-
vere psychosis. He continued to worsen clinically, and
expired due to lymphoma progression on day 166 af-
ter initial lymphoma diagnosis, and 200 days after the
onset of signs and symptoms. 
PaTIEnT 3
Patient 3 was a 44-year old male (men sex male), who
had been diagnosed HIV-positive for 7 years (Cd4-
count  120/µl,  Cd4/8-ratio  0.2,  viral  load  793.000
copies/ml; aRT-na￯ve). He had a history of seasonal
allergies,  primary  syphilis,  gonorrhoea,  and  condylo-
mata  accuminata.  He  was  hospitalized  after  a  first
grand mal episode. a CCT scan revealed a contrast-
enhancing temporal mass with a diameter of 1.2cm ac-
companied  with  perifocal  oedema.  The  spinal  fluid
was HsV-consensus-PCR negative. despite one week
of  empiric  toxoplasmosis  therapy,  the  mass  had  ex-
panded to a diameter of 2cm. stereotactic brain biop-
sy  showed  an  EBV  induced  lymphoproliferation
(lMP+,  EBna-2+,  Cd30-,  Cd20+,  high  prolifera-
tion-index  kI-67).  due  to  the  presence  of  massive
necrosis and high proliferation index, highly malignant
lymphoma was suspected, but could not be confirmed
with  the  biopsy  specimen  material.  since  a  repeat
biopsy would have put the patient at further risk, these
highly suspicious results were deemed consistent with
the clinical presentation, and treatment was initiated
with foscarnet, interleukin-2, high dose aZT for 18
days,  with  lamivudine  and  lopinavir/  ritonavir  bid
added for HaaRT in standard doses. due to a second
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tered since the first seizure, was raised from 1200mg
to 2100mg daily. There was no change demonstrated
by CCT scan. 
overall, he tolerated the treatment regimen well ex-
cept for limb edema, which improved with xipamid
10mg, and one episode of local induration at an inter-
leukin injection site that resolved without sequelae. a
CCT scan on day 18 showed a tumor diameter of 2.5-
3cm with no change in perifocal oedema. There were
no signs of compression. His Cd4-count on day 11
was 550/µl, Cd4/Cd8 ratio 2.0, and on day 30 it was
180/µl, with a ratio of 0.7, and a viral load of 790
copies/ml. HaaRT (aZT, 3TC, lPV/r) was contin-
ued, and ganciclovir maintenance therapy (once daily
5mg per bodyweight) was initiated. forty two days af-
ter treatment initiation, the patient underwent whole
brain radiotherapy with a 30 gy cumulative dose. six
months after start of treatment, his HIV viral load
was  constantly  below  detectable  levels,  and  after  4
months, CCT scan showed CR with leukencephalopa-
thy.  after  completion  of  3  months  of  ganciclovir
maintenance  therapy,  the  patient  received  cidofovir
monthly for one year after the induction period (cu-
mulatively  20  times)  against  EBV  proliferation  be-
cause of his relatively low Cd4-count (nadir 100/µl
after 6 months). The cidofovir was then discontinued
due to a steadily improving immune response (Cd4-
count 306/µl). ophthalmological and neurological ex-
aminations as well as renal function tests were within
normal  limits  2  years  after  the  start  of  treatment.
four  years  from  time  of  diagnosis,  CCT  restaging
demonstrated constant marked demyelinization of the
cerebral medullary layer, which was most likely radio-
therapy-associated. The patient has been clinically and
mentally  stable  53  months  after  diagnosis.  He  re-
mained  on  HaaRT  with  aZT,  3TC,  lPV/r  with
Cd4-counts above 300/µl and without a detectable
viral load. a year after diagnosis the patient retired
from work.
oVERall REsulTs
Combined first-line therapy with HaaRT, Il-2, fos-
carnet and aZT-high-dose was not effective in reduc-
ing tumour growth in the 3 patients. Therefore, stan-
dard radiation therapy was indicated after 2 weeks of
therapy  in  all  patients.  after  4  months  of  radiation
therapy, patient 3 showed a complete remission of the
tumour mass 53 months after diagnosis and a stabi-
lized immune response by HaaRT as well as cidofovir
maintenance-therapy (20 cycles). However, only EBV-
lymphoproliferation  was  proven  histologically.  lym-
phoma was suspected because of the high prolifera-
tion index and necrotic tissue masses. Retrospectively,
based upon the positive response to radiation and ab-
sence  of  an  early  response  to  immunomodulating
therapy,  a  diagnosis  of  lymphoma  (or  a  preliminary
stage of it) was likely.
The two-week course of therapy in the 3 patients
was well tolerated. adverse events including hemato-
logical drug reactions were few and resolved with min-
imal treatment. There was no common toxicity criteria
(CTC) grade 3 or 4 toxicity.
dIsCussIon
although these case reports shared comparable clini-
cal characteristics to those treated by Raez et.al. [1],
they  did  not  have  similar  results  despite  having  re-
ceived  optimized  antiviral  medication  with  foscarnet
instead of ganciclovir and demonstrating excellent im-
mune responses in 2 of the 3 patients (patient 1 was
not  evaluated  for  an  immune  response).  Combined
therapy with Il-2, aZT, foscarnet and HaaRT had
no effects on reducing tumour growth in our aRT-
naive HIV-positive patients with PCnsl in the short
time  of  administration.  By  comparison,  this  differs
from Raez et.al, who reported at least partial remission
within two to three weeks in 4 out of 5 patients.
These case reports suggest that this was probably
due to rapid PCnsl tumour growth and that aZT,
which was the only anti-neoplastic agent, was ineffec-
tive  against  lymphoma  cell  lines  [1].  This  finding  is
concordant to different highly toxic treatment experi-
ences both in HIV-positive and HIV-negative PCnsl
patients [4, 7, 8, 16].
HaaRT  was  effective  in  immune  reconstitution,
but patient 2 did not take it regularly from the time of
radiation therapy due to poor adherence. 
Replacing  ganciclovir  by  foscarnet  during  the  in-
duction phase helped to avoid the hematological toxic-
ity of ganciclovir. Both agents as well as cidofovir are
effective  against  EBV  [25,  27].  foscarnet  has  been
shown to be effective in EBV-associated lymphopro-
liferations and is activated independently of viral en-
coded  thymidine-kinase,  which  is  an  advantage  over
ganciclovir [28]. However, it was not effective in halt-
ing rapid tumor growth in these patients, which had al-
ready become independent from the original multifac-
torial pathogenesis of polyclonal EBV- and HIV-in-
duced  lymphoproliferation.  since  the  herpes-virus
consensus PCR was negative in two of the patients’
Csf prior to therapy, and not performed in one pa-
tient (histological diagnosis), EBV-viral load was not
measured. 
The reason for the reduced effectiveness of foscar-
net compared to ganciclovir against EBV could be not
be discerned, and it is unclear why Raez and aboulafia
elected to utilize ganciclovir.
Interleukin-2 was administered to induce an acceler-
ation  of  immune  response,  and  to  decrease  EBV-
dna [29]. Its clinical benefit in reducing opportunis-
tic infections in HIV positive persons is not proven
[30].  The  observed  rapid  immune  reconstitution  of
Cd4 cells by combined antiretroviral and interleukin-2
administration in 2 patients was impressive, neverthe-
less it had no impact on tumour progression. of note
is that this did eventually contribute to stopping lym-
phoproliferation after radiation in patient 3, which is
similar to four reported patients with longer lasting re-
missions by HaaRT and radiation [4].
Even though only lymphoproliferation had been di-
agnosed  in  patient  3,  the  lymphoproliferative  poly-
clonal  tumor  with  impressive  necrotic  tissue  mass,
which is pathognomonic for high grade lymphoma in
the brain, was highly suspicious for PCnsl. Polyclon-
al lymphoproliferation as a pre-lymphoma stage could
not be completely ruled out.
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Patient 2
a),  b)  diffuse  large  B-cell  lym-
phoma within the central nervous
tissue penetrating a blood vessel. c)
The  large  tumor  cells  express  the
B-cell  marker  Cd20  and  reveal  a
high proliverative activity d). 
Patient 1
e) In a further case H&E stained
section shows a diffuse large B-cell
lymphoma. nearly all of the lym-
phoma cells show prominent cen-
tral nucleoli. f) The tumor cells are
reactive  with  antibodies  against
Cd20. g) The mature T-cell react
with  antibodies  against  Cd3.  h)
The  proliferation  marker  MiB1
(ki67) labels more than 50% of the
tumor cells. 
Patient 3
i, j) The H&E stained sections re-
veal necrotic cns tissue with reac-
tive  astrocytes,  macrophages  and
inflammatory  cells.  k)  with  anti-
bodies against Cd20 some blastic
B-cells  where  detectable.  l)  The
proliferation  marker  Mib1  labels
only some inflammatory cells.
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relatively stable immune status and without previ  ous
aIds-defining illnesses at the time of diagnosis. Her-
pes-consensus  PCR  in  his  Csf  was  negative  with
EBV-positivity in histology, corresponding to a latent
infection pattern without active EBV-replication. 
Ritonavir has been reported to have antiangiogenic
and radiation sensitizing effects in a mouse carcinoma
model [31], and could eventually have had an influence
on response, but only in this patient. However, after
responding  to  radiation  he  continued  HaaRT  with
long-term antiviral EBV therapy and was clinically sta-
ble over the following years.
HaaRT plus whole brain radiation appears to be
the mainstay of treatment for HIV-associated PCnsl-
patients  with  highly  impaired  immune  and  perfor-
mance status. 
In selected cases of HIV-positive PCnsl patients
with  sufficient  performance  status,  systemic  chemo  -
therapy  should  be  considered  [16,32].  HaaRT  and
systemic chemotherapy, possibly even in patients with
impaired immune status, can be considered in an at-
tempt to induce immune reconstitution and thus im-
proving both neurological and overall clinical status. 
Combination  chemo-radiotherapies  in  immuno-
competent  patients  (most  of  them  with  intrathecal
MTX and/or cytarabine, systemic methotrexate, pro-
carbazine, vincristine, thiotepa, teniposide or carmus-
tine)  cause  high  rates  of  hematologic  toxicity,  treat-
ment-related deaths in up to 10%, infection rates up to
19%  and  leukoencephalopathy  rates  of  up  to  30%
(without  radiation  3%).  The  median  survival  ranged
from 32 to 55 months [7-9]. 
systemic rituximab alone does not generally seem
to be beneficial, but may be so only in selected pa-
tients [9, 33]. In a small series with relapsed or pro-
gressive  disease  in  HIV-negative  persons,  intrathecal
rituximab was shown to be safe and partially effective
[34-36] and therefore stands as a possible option.
systemic methotrexate (MTX) alone, 3-8 g/mﾲ and
delayed radiotherapy are most frequently used in HIV-
negative patients, and show median survival times of
22 to 47 months with low neurotoxicity rates. [7-9]. 
select  HIV  patients  are  reported  to  benefit  from
high-dose MTX alone: seven out of 15 patients treat-
ed  with  3g/mﾲ  intravenous  MTX  without  HaaRT
showed a complete response after six cycles, with two
of 15 patients dying from septicaemia [32]. only a few
HIV-positive patients with PCnsl were treated with
systemic MTX [4, 32]. 
In  the  pre-HaaRT  era,  combined  radio-chemo  -
therapy with procarbazine, lomustine and vincristine
(PCV-3) for HIV-related PCnsl patients with more
than 200 Cd4-cells/µl, who had a good performance
status and without history of opportunistic infection,
showed a median survival of 13 months [16]. 
autologous stem-cell rescue with high-dose chemo  -
therapy protocols were given successfully in immuno-
competent PCnsl patients under the age of 60 years
and  achieved  median  survival  rates  of  up  to  60
months  [11,  12,  37].  HIV-positive  patients  were  ex-
cluded from high-dose studies due to safety reasons.
Temozolomide plus systemic MTX/ prednisone in
an elderly patient group showed overall survival rates
of 36 months, but severe nephrotoxicity and hemato-
logical toxicity occurred in 20% and 13% respectively
[38] which is too toxic for aIds-patients. a promising
schedule for the elderly that utilizes three cycles of rit-
uximab,  methotrexate,  lomustine,  and  procarbacine
(R-MCP) has been described. The regimen is without
radiation, has an acceptable safety profile, and a 12-
month overall and disease-free survival of 81% in 16
patients [14]. This treatment modality could eventually
become an option for HIV-positive PCnsl patients,
considering that the oldest patient was 83 years old
and that a reduced performance status was not an ex-
clusion criteria.
salvage regimens have been performed with topote-
can, PCV (procarbacine, lomustine, vincristine), antra-
cyclines,  high-dose  cytarabine,  etoposide,  ifosfamide,
thiotepa, temozolomide, temozolomide/rituximab, ra-
diotherapy and surgery [7, 8, 24, 39]. It remains un-
clear which of these can be considered in HIV-posi-
tive patients.
ConClusIon
Il-2,  HaaRT,  aZT-high-dose  and  foscarnet  were
safe, but ineffective when used as the only therapy for
HIV-associated PCnsl based on our experience with
these 3 patients. a review of results in the medical lit-
erature is also inconsistent. The numbers of patients
treated with similar regimens have been too few to al-
low  any  final  conclusion.  The  deterioration  of  the
overall clinical status in 2 out of 3 patients was rapid,
and corresponded to the frequently encountered clini-
cal course of newly diagnosed HIV-associated PCnsl
patients, who often have co morbidities. nevertheless,
in select patients with advanced disease and without a
systemic chemotherapeutic option, this type of regi-
men could be considered.
Raez and aboulafia et al reported similar cases to
the  3  patients  that  we  have  described.  a  favourable
clinical course may more likely occur in select HIV in-
fected  patients  with  good  performance  status.  Two 
of  the  3  patients  had  severe  co  morbidities  (TBC, 
kaposi-sarcoma,  cryptococcosis,  psychosis),  so
chemo  therapy was not a reasonable option. Therefore,
this regimen was considered to be potentially benefi-
cial. In the future, patients within clinical studies who
have  adequate  performance  status  could  qualify  for
more  intensive  systemic  chemotherapy  options  com-
bined with HaaRT to avoid late leukencephalopathy
caused by radiation. It remains uncertain if interleukin-
2, aZT high-dose and / or foscarnet can be added or
be given sequentially with chemotherapy, especially in
severe compromised patients at the beginning of ther-
apy. despite a substantial and sustained increase in the
Cd4-count,  as  compared  with  antiretroviral  therapy
alone, interleukin-2 plus antiretroviral therapy yielded
no clinical benefit in HIV positive persons [30]. 
Regardless,  most  HIV-associated  PCnsl  patients
are  not  cured  with  systemic  chemotherapy  [6].  If
chemotherapy  is  utilized,  multidisciplinary  teams  in-
cluding  specialists  in  haematology-oncology  and 
infectious diseases will be needed to manage toxicities,
drug-interactions,  and  specific  infectious  and  other
complications that can occur during and after therapy. 
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treating Cns-lymphoma and other types of cancer in
HIV positive patients, and should be encouraged by
the improved prognosis due to HaaRT to treat Cns-
lymphomas more intensively [18]. 
finally, we emphasize the importance of perform-
ing clinical trials in HIV-positive patients with malig-
nancies.
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